[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569955":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":28,"collaborators":7,"id":30,"slug":7,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":7,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":7,"studyType":42,"phases":7,"briefSummary":43,"conditions":44,"keywords":7,"overallStatus":46,"whyStopped":7,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":56},{"fullName":5,"class":6},"Shanghai Mental Health Center","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"YU, Prof.","CONTACT","+86 021-3477-3299","yushunying@smhc.org.cn",[15],{"facility":5,"status":7,"city":16,"state":7,"zip":7,"country":17,"countryCode":18,"cosmosGeoPoint":19,"geoPoint":24,"contacts":25},"Shanghai","China","CN",{"type":20,"coordinates":21},"Point",[22,23],121.45806,31.22222,{"lat":23,"lon":22},[26],{"name":27,"role":11,"phone":12,"phoneExt":7,"email":13},"Yu, Prof.",{"type":29,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100569955",false,"NCT06700967","Evaluating Pharmacogenomics-Based Pharmacotherapy in Real-World Settings for Schizophrenia","A Precision Medication Guidance Model for Schizophrenia Based on Pharmacogenomics and Physiologically Based Pharmacokinetics: a Real-World Observational Study","Inclusion Criteria:\n\n1. Suffer from schizophrenia (as assessed in agreement with ICD-11 criteria).\n2. Age between ≥18 and \\\u003C65 years.\n3. Currently receiving inpatient or outpatient psychiatric treatment.\n4. Experienced any of the following suboptimal treatment conditions while receiving antipsychotic medication within the therapeutic dosage range:\n\n   1. Standard antipsychotic treatment for more than 2 weeks with the occurrence of drug-induced adverse effects requiring dose adjustment or a switch of medication.\n   2. Antipsychotic treatment within the therapeutic dosage range for more than 4 weeks, with the presence of at least two items of the Positive and Negative Syndrome Scale (PANSS) (P1, P2, P3, N1, N4, N6, G5, and G9) score ≥4, or a total PANSS score \\>70, or a CGI-S score ≥4.\n   3. Other situations where a change in medication is deemed necessary, as assessed by senior clinical physicians.\n5. Understand the study requirements and provide written informed consent to participate; a signed and dated informed consent form (ICF) will be obtained from each patient before participation in the study.\n\nExclusion Criteria:\n\n1. Presence of organic brain disease or a severe and\u002For unstable physical condition.\n2. Substance abuse or dependence within the past 6 months or currently.\n3. Presence of elevated levels of agitation, impulsivity, or risk of self-injury or suicide.\n4. Pregnant or breastfeeding women.\n5. The presence of any other conditions that may render the individual ineligible for participation in this clinical trial.","ALL","18 Years","65 Years",{"count":40,"type":41},400,"ESTIMATED","OBSERVATIONAL","An 8-week, rater-blinded, real-world observational study to investigate the benefits of pharmacogenetics-based pharmacotherapy in patients suffering from schizophrenia.",[45],"Schizophenia Disorder","NOT_YET_RECRUITING","2024-11-20",{"date":49,"type":50},"2024-11-22","ACTUAL",{"date":52,"type":41},"2024-12-01",{"date":54,"type":41},"2025-12-31",{"name":5,"class":6},1]